Daniel J. Starks - Apr 26, 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
Director
Signature
/s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Apr 26, 2024
Transactions value $
$0
Form type
4
Date filed
4/30/2024, 06:22 PM
Previous filing
Oct 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +1.87K +0.03% $0.00 6.73M Apr 26, 2024 Direct F1
holding ABT Common shares without par value 258 Apr 26, 2024 Alynne Starks 2012 Irrevocable Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +5.28K $0.00 5.28K Apr 26, 2024 Common Shares 5.28K $107.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2 Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F3 Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.